Piper Sandler raised the firm’s price target on Myriad Genetics to $28 from $23 following quarterly results. The firm keeps a Neutral rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Leerink upgrades Myriad Genetics to Outperform as transformation turns a corner
- Myriad Genetics upgraded to Outperform from Market Perform at Leerink
- Myriad Genetics sees FY24 adjusted EPS 0c-5c, consensus 2c
- Myriad Genetics reports Q1 EPS (1c), consensus (10c)
- Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business
